The current study aimed to construct a prognostic predictive model based on tumor microenvironment. CIBERSORT and ESTIMATE algorithms were used to reveal the immune cell infiltration (ICI) landscape of colon cancer. Patients were classified into three clusters by ConsensusClusterPlus algorithm. ICI scores of each patient were determined by principal component analysis. Patients were divided into high and low ICI score groups. Survival, gene expression, and somatic mutation of the two groups were compared. We found that patients with no lymph node invasion, no metastasis, T1–2 disease, and stage I–II had higher ICI scores. Calcium signaling pathway, leukocyte transendothelial migration pathway, MAPK signaling pathway, TGF β pathway, and Wnt signaling pathway were enriched in the high ICI score group. Immune-checkpoint and immune-activity associated genes were decreased in high ICI score patients. Patients in the high ICI score group had better survival. Prognostic value of ICI score was independent of tumor mutational burden (TMB). The ICI score model constructed in the current study may serve as an independent prognostic biomarker in colon cancer.
Original Article The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma Hanwen Huang, Weibin Wu, Yiyu Lu, Xiaofen Pan
Background: Expression level of HIST1H1D, a linker histone H1 gene, was reported to be associated with poor prognosis in some malignant tumors. Online database showed that HIST1H1D was increased in esophageal carcinoma. The current study aimed to evaluated the role of HIST1H1D in esophageal carcinoma using online data from The Cancer Genome Atlas (TCGA).Methods. Wilcoxon signed-rank test, cox regression analysis and multivariant analysis were used to analyze the relationship between clinical characteristic and HIST1H1D expression level. Kaplan-Meier method was used to analyze the association of HIST1H1D and overall survival. Gene set enrichment analysis (GSEA) was used to identify HIST1H1D-related signaling pathway.Results. Compared to normal sample, HIST1H1D was significantly increased in esophageal carcinoma sample (p=0.000). High HIST1H1D expression was associated with poor survival (p=0.035). Univariate analysis showed that high HIST1H1D expression was associated with a poor overall survival (HR:1.19, 95% confidence interval [CI]: 1.05-1.34, p=0.01). Multivariate analysis indicated that HIST1H1D remained an independent prognostic predictor of overall survival (HR:1.18, 95% confidence interval [CI]: 1.02-1.36, p=0.03). GSEA revealed that alpha linolenic acid metabolism, arachidonic acid metabolism, histidine metabolism, vascular smooth muscle contraction, primary bile acid biosynthesis, phenylalanine metabolism and ether lipid metabolism were enriched in HIST1H1D high expression phenotype.Conclusions: HIST1H1D may sever as a potential prognostic predictor of poor survival in esophageal carcinoma. Lipid metabolism, histidine metabolism, vascular smooth muscle contraction, primary bile acid biosynthesis, phenylalanine metabolism and ether lipid metabolism may be the key signaling pathway regulated by HIST1H1D.
Purpose To study the safety of resuming antitumor therapy in tumor patients infected with COVID-19. Methods We collected the clinical information of patients with tumors who were infected with COVID-19 and resume antitumor therapy between December 2022 and June 2023. Information about antitumor therapy, COVID-19-related symptoms, laboratory tests, antitumor therapy-related adverse events (AEs), and re-infection with COVID-19 were recorded. Primary endpoints included the incidence of AEs and re-infection of COVID-19. The secondary endpoints included the incidence and duration of COVID-19 related symptoms. Results The most common COVID-19 symptoms were fever (39.5%), cough (37.2%), and fatigue (44.2%). Most patients’ symptoms lasted no more than a week Two patients were re-infected with COVID-19. All-grade AEs with an incidence rate > 10% included anemia, increased gamma-glutamyl transferase (GGT), anorexia, neutropenia, hypocalcemia, leukopenia, thrombocytopenia, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, and nausea. Grade 3–4 AEs with an incidence rate higher than 5% included anemia, neutropenia, leukopenia, thrombocytopenia, anorexia, and vomiting. The incidence of AEs before and after COVID-19 infection did not show a significant difference. Conclusion Resuming antitumor therapy early after SARS-CoV-2 test turned negative did not increase antitumor therapy-related AEs or the incidence of re-infection in COVID-19 infection patients.
Objectives This study aimed to compare the survival outcomes of paclitaxel liposome-based chemoradiotherapy, with or without rhEndostatin, in patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Methods Patients with ESCC treated with paclitaxel liposome-based definitive chemoradiotherapy (dCRT), with or without rhEndostatin (E), between February 2015 and June 2020 were included. Patients received induction chemotherapy followed by concurrent chemoradiotherapy, with or without rhEndostatin. The chemotherapy regimen consisted of platinum-based doublet (paclitaxel liposome + cisplatin/nedaplatin). RhEndostatin was administered at a dose of 30 mg/d from day 1 to day 5 of each chemotherapy cycle. Total radiotherapy dose was 66–68 Gy, delivered in fractions of 2.0–2.2 Gy/d. Follow-up continued until December 2023. The primary endpoints were 3-year progression-free survival (PFS) rate. Secondary endpoints included 3-year overall survival (OS) rate, objective response rate (ORR), disease control rate (DCR), and toxicity. Results A total of 80 patients were included, with 34 in the dCRT group and 46 in the E + dCRT group. The 3-year PFS was 26.47% (95% confidence interval [CI] 13.19–41.81) in the dCRT group and 56.29% (95% CI 40.79–69.20) in the E + dCRT group (Hazard ratio (HR), 0.50; 95% CI 0.28–0.89, P = 0.012). Patients in the E + dCRT group had a superior 3-year OS compared to those in the dCRT group (80.44% [95% CI 65.77–89.30] vs. 47.06% [95% CI 29.83–62.52]; HR, 0.40; 95% CI 0.21–0.72; P = 0.003). The ORR was 91.18% in the dCRT group and 95.65% in the E + dCRT group. The most common grade 3–4 toxicities were leukopenia, neutropenia, and thrombocytopenia. Conclusion The addition of rhEndostatin to paclitaxel liposome-based dCRT may improve clinical outcomes for patients with unresectable ESCC while maintaining manageable toxicities. However, further prospective randomized controlled studies are necessary to confirm the survival benefits of this treatment strategy.
Background: Previous research has found a link between the temperature of food and beverages and the risk of esophageal cancer (EC). A causal relationship between the two has not been well established. Herein, we used Mendelian randomization (MR) analysis to assess the causal effect of temperature preference for hot beverages on EC risk. Methods: Genome-wide association studies (GWAS) data for hot beverage temperature preference were obtained from the UK biobank. There were 457,873 European and 2,617 East Asian participants included. GWAS data for EC were obtained from the Integrative Epidemiology Unit (IEU) project database. Two datasets from the European population and two datasets from the East Asian population were included. Totally, 4,426 EC cases and 1,202,270 control subjects were included. The “TwoSampleMR” R package was used to conduct a two-sample MR analysis. A random-effect inverse variance weighted (IVW) was used as the main analytical method to estimate the causal effect, and various sensitivity analyses, including MR Egger, weighted median, simple mode, and weighted mode, were used to examine the potential violation of the second and third MR assumptions. Meta-analyses were performed to further confirm the results. Results: Sixty-eight single nucleotide polymorphisms (SNPs) from the European population and 11 SNPs from the East Asian population were used for MR analysis. No significant causal effect was found between hot beverage temperature preference and EC risk in the European population {for the ieu-b-4960 dataset, inverse variance weighted odds ratio (ORIVW) =1.00 [95% confidence interval (CI): 0.99–1.00], P=0.54; for the ebi-a-GCST90018841 dataset, ORIVW =0.35 (95% CI: 0.10–1.29), P=0.12} or in the East Asian population [for the bbj-a-117 dataset, ORIVW =1.09 (95% CI: 0.80–1.48), P=0.59; for the ebi-a-GCST90018621 dataset, ORIVW =0.11 (95% CI: 0.82–1.50), P=0.49]. Meta-analyses of the European population datasets and the Asian population datasets showed consistent results. Conclusions: The current MR analysis provides new genetic evidence for a null causal relationship between hot beverage temperature preference and EC, both in the European population and the East Asian population. Evidence to prevent EC by reducing the intake of hot beverages is insufficient.